Order Article Reprints

Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendón Y, Bianchini D, Llacer C, et al. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers. 2021; 13(10):2334. https://doi.org/10.3390/cancers13102334

Lozano, Rebeca, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, Joaquim Mateo, Alison H. M. Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llacer, and et al. 2021. "Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients" Cancers 13, no. 10: 2334. https://doi.org/10.3390/cancers13102334

Lozano, R., Lorente, D., Aragon, I. M., Romero-Laorden, N., Nombela, P., Mateo, J., Reid, A. H. M., Cendón, Y., Bianchini, D., Llacer, C., Sandhu, S. K., Sharp, A., Rescigno, P., Garcés, T., Pacheco, M. I., Flohr, P., Massard, C., López-Casas, P. P., Castro, E., ... Olmos, D. (2021). Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers, 13(10), 2334. https://doi.org/10.3390/cancers13102334